Concluding Remarks

In: SpringerBriefs in Reproductive Biology · 2015 · pp. 113–115 · doi:10.1007/978-3-319-18308-4_11 · W4249389559
book-chapter OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
AI-generated summary by claude@2026-06+body, 2026-06-08

This chapter provides concluding remarks on endometriosis, a common gynecological disease affecting millions of reproductive-age women worldwide and characterized by pain and reduced fertility.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-08

This chapter provides concluding remarks on endometriosis, describing it as a common and complex debilitating gynecological disease affecting reproductive-age women worldwide and in the United States. It summarizes that the main symptoms are pain and reduced fertility, emphasizing the disease burden. The piece is limited in detail because it functions as a brief concluding section rather than presenting new analyses or methods. This paper is centrally about endometriosis — it concludes a SpringerBriefs chapter by summarizing prevalence and the core symptoms of pain and reduced fertility.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK